

## Diaceutics Opens US Headquarters

*New US office in New Jersey will facilitate growth of local sales & marketing teams close to Diaceutics' pharma customers*

**New York, Belfast and London, 14 January 2025 - Diaceutics PLC** (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that it has opened its new US Headquarters (HQ) in Newport, New Jersey, in close proximity to the majority of its Life Science customers in the Northeastern US.

The US market represents around 90% of Diaceutics' revenue and the new US HQ will facilitate the further expansion of its US focused sales & marketing operations and follows on from the successful recruitment of a number of senior sales personnel in the US during 2024. Diaceutics' US HQ will provide a commercial hub, with associated facilities, for all the Company's US based personnel and will accommodate non-US based personnel whilst they are travelling in the US.

The planned expansion of Diaceutics' US sales and marketing operations will lead to a significant number of new commercially focused personnel joining the team, with the majority based at the US HQ.

As Diaceutics continues to grow its US business, and in particular rolls out its full toolkit of pharma and biotech commercialisation solutions, the geographical location of customer facing teams is essential given the level of partnership and collaboration between the Company and its customers.

**Madeline Brown, VP Chief of Staff at Diaceutics, commented:** *"The US market is crucial to our future growth plans and we are excited to continue to grow our business and presence in the US. In 2024, we have had significant success recruiting senior US based sales and management personnel, and opening our US HQ enables us to deepen our partnerships with US based life science customers."*

**Enquiries:  
Diaceutics PLC**

Ryan Keeling, Chief Executive Officer  
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500  
[investorrelations@diaceutics.com](mailto:investorrelations@diaceutics.com)

**Canaccord Genuity Limited (Nomad & Broker)**

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

**About Diaceutics**

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDGGDBUBBDGUX